ReviewJournal of clinical medicine2022
Crescents and IgA Nephropathy: A Delicate Marriage.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Predictive role of Oxford Classification for prognosis in children with IgA nephropathy: a systematic review and meta-analysis.Renal failure · 2024Pooled it
- Clinical, laboratory, and pathological correlates of crescent formation in biopsy-proven pediatric IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2026Article
- High complement activation index predicts renal progression in crescentic IgA nephropathy.Frontiers in immunology · 2026Article
- Impact of crescents on the immunosuppression treatment of IgA nephropathy.Renal failure · 2025Article
- Points of view in nephrology: personalized management of IgA nephropathy, beyond KDIGO.Journal of nephrology · 2024Review
- Crescents proportions above 10% are associated with unfavorable kidney outcomes in IgA nephropathy patients with partial crescent formation.Renal failure · 2023Article
- Long-term follow-up of IgA nephropathy: clinicopathological features and predictors of outcomes.Clinical kidney journal · 2023Article
- Evaluating Progression Risk in Patients With Immunoglobulin A Nephropathy.Kidney international reports · 2023Review
- Long-term follow-up of an IgA nephropathy cohort: outcomes and risk factors.Renal failure · 2023Article
- The Effects ofPharmaceuticals (Basel, Switzerland) · 2023Review
- A novel clinical-radiomic nomogram for the crescent status in IgA nephropathy.Frontiers in endocrinology · 2023Article
- Special Issue: New Insights into the Pathogenesis and Therapies of IgA Nephropathy.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is a progressive disease with great variability in the clinical course. Among the clinical and pathologic features contributing to variable outcomes, the presence of crescents has attracted particular interest as a distinct pathological feature associated with severity. Several uncontrolled observations have led to the general thought that the presence and extent of crescents was a prognostic indicator associated with poor outcomes. However, KDIGO 2021 guidelines concluded that either the presence or the relative number of crescents should not be used to determine the progression of IgAN nor should they suggest the choice of immunosuppression. Our aim is to report and discuss recent data on the debated issue of the value of active (cellular and fibrocellular) crescents in the pathogenesis and clinical progression of IgAN, their predictive value, and the impact of immunosuppression on renal function. We conclude that the value of crescents should not be disregarded, although this feature does not have an independent predictive value for progression in IgAN, particularly when considering immunosuppressed patients. An integrated overall evaluation of crescents with other active MEST scores, clinical data, and novel biomarkers must be considered in achieving a personalized therapeutic approach to IgAN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.